Novo Nordisk (NVO) stock vs the S&P 500 and pharmaceutical stocks
As of 12 October 2026, Novo Nordisk (NVO) is trailing both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.
Where Novo Nordisk stands now
As of 12 October 2026, Novo Nordisk is behind the S&P 500 on every window Zensei tracks, from one month to one year. The market has preferred other stocks for some time.
Inside its group, NVO lags: it is behind pharmaceutical stocks (PPH) over both the past month and three months. As a group, pharmaceutical stocks are trailing the S&P 500 right now. Stock and group are both under pressure.
Novo Nordisk is 5.6% of PPH, so its moves weigh on the fund. The thing to watch is the past month: a turn against the market usually shows there first.
Novo Nordisk competitors and peers
The largest other holdings of VanEck Pharmaceutical ETF (PPH), by weight in the fund, with their plain return over the past month.
Is Novo Nordisk in the S&P 500?
As of 12 October 2026, Novo Nordisk is not in the S&P 500. Zensei groups it with pharmaceutical stocks (PPH), where it has 5.6% weight.
None of the 11 S&P 500 sector funds holds it. See Pharmaceutical Stocks (PPH)
Novo Nordisk ETF: the funds that hold NVO
One fund that Zensei tracks holds NVO. The main sector is the fund Zensei groups it with. The other funds follow by weight.
NVO stock performance: 1-month, 3-month and 1-year vs the S&P 500
Novo Nordisk and the S&P 500 (SPY) side by side, over each window Zensei tracks.
Prices as of · computed from daily adjusted closes · how we measure
NVO against pharmaceutical stocks, in depth
See the size of the gap between Novo Nordisk and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.
See the full analysisNovo Nordisk stock: common questions
Who are Novo Nordisk's competitors?
As of 12 October 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) by weight are Eli Lilly (LLY), Merck & Co Inc (MRK), Pfizer (PFE), McKesson Corp (MCK), Bristol-Myers Squibb Co (BMY). These are the stocks Novo Nordisk sits next to among pharmaceutical stocks.
Which ETFs hold Novo Nordisk?
As of 12 October 2026, one fund that Zensei tracks holds NVO. Zensei groups it with pharmaceutical stocks in VanEck Pharmaceutical ETF (PPH), where its weight is 5.6%.
Is Novo Nordisk in the S&P 500?
As of 12 October 2026, Novo Nordisk is not in the S&P 500. Zensei groups it with pharmaceutical stocks (PPH), where it has 5.6% weight.
What sector is Novo Nordisk in?
As of 12 October 2026, Zensei groups Novo Nordisk with pharmaceutical stocks (PPH, its primary fund).
Is Novo Nordisk stock beating the S&P 500?
As of 12 October 2026, Novo Nordisk (NVO) is down 10.4% over the past month. The S&P 500 is up 2.1% over the same month. Over three months, the stock is down 20.7% and the S&P 500 is up 4.1%.
Is Novo Nordisk doing better than other pharmaceutical stocks?
As of 12 October 2026, Novo Nordisk (NVO) is behind pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.
Recent changes
- ·Among the weakest → trailing the market and pharmaceutical stocks
- ·First tracked: among the weakest
Track Novo Nordisk against pharmaceutical stocks and the market
Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.